Merz Aesthetics Announces FDA Approval Of XEOMIN®

Merz Aesthetics Announces FDA Approval Of XEOMIN® (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients


SAN MATEO, Calif., July 21, 2011 /PRNewswire/ -- Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN® (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

"The FDA approval of XEOMIN is a significant milestone for Merz Aesthetics and a promising addition to our entire aesthetics franchise," said Dennis Condon, President and Chief Business Officer of Merz Aesthetics, Inc. "We are confident that XEOMIN will provide patients and physicians with a new option for improving the appearance of glabellar lines."


"XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials," said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, Clinical Associate Professor of Medicine at the University of California in Los Angeles, Calif., and Director of Skin Care and Laser Physicians in Beverly Hills, Calif.